AGL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AGL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Agilon Health's change in receivables for the quarter that ended in Dec. 2023 was $0 Mil. It means Agilon Health's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .
Agilon Health's change in receivables for the fiscal year that ended in Dec. 2023 was $-460 Mil. It means Agilon Health's Accounts Receivable increased by $460 Mil from Dec. 2022 to Dec. 2023 .
Agilon Health's Accounts Receivable for the quarter that ended in Dec. 2023 was $942 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Agilon Health's Days Sales Outstanding for the three months ended in Dec. 2023 was 105.46.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Agilon Health's liquidation value for the three months ended in Dec. 2023 was $115 Mil.
The historical data trend for Agilon Health's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agilon Health Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Change In Receivables | -23.28 | -59.38 | -149.04 | -204.17 | -460.37 |
Agilon Health Quarterly Data | |||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Change In Receivables | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agilon Health (NYSE:AGL) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Agilon Health's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 942.461 | / | 815.504 | * | 91 |
= | 105.46 |
2. In Ben Graham's calculation of liquidation value, Agilon Health's accounts receivable are only considered to be worth 75% of book value:
Agilon Health's liquidation value for the quarter that ended in Dec. 2023 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 488.343 | - | 1079.845 | + | 0.75 * 942.461 | + | 0.5 * 0 |
= | 115 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Agilon Health's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey A. Schwaneke | director | C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723 |
Steven Sell | director, officer: CEO & President | C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723 |
Benjamin Shaker | officer: Chief Markets Officer | C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723 |
Timothy Gertsch | officer: Chief Accounting Officer | C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723 |
Silvana Battaglia | director | 227 WASHINGTON STREET, CONSHOHOCKEN PA 19428 |
Cd&r Investment Associates Ix, Ltd. | 10 percent owner | MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, GRAND CAYMAN E9 KY101194 |
Veeral Desai | officer: Chief Strategy & Dev. Officer | C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723 |
Benjamin Kornitzer | officer: Chief Med. & Quality Officer | C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723 |
John William Wulf | director | C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723 |
Diana Mckenzie | director | METLIFE, 200 PARK AVENUE, NEW YORK NY 10166 |
Priscilla Kasenchak | officer: Chief Accounting Officer | 1111 MARCUS AVENUE, LAKE SUCCESS NY 11042 |
Michael L Smith | director | C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723 |
Theodore Halkias | officer: Chief Business Officer | C/O AGILON HEALTH, INC., 1 WORLD TRADE CENTER, SUITE 2000, LONG BEACH CA 90831 |
Joan Danieley | officer: Chief Administrative Officer | C/O AGILON HEALTH, INC., 1 WORLD TRADE CENTER, SUITE 2000, LONG BEACH CA 90831 |
Glenn Sobotka | officer: Chief Accounting Officer | C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723 |
From GuruFocus
By Business Wire Business Wire • 04-20-2023
By PRNewswire • 01-23-2024
By PRNewswire • 01-22-2024
By Business Wire • 06-22-2023
By Business Wire Business Wire • 03-30-2023
By Business Wire • 01-05-2024
By Business Wire • 11-01-2023
By GuruFocus Research • 09-14-2023
By Business Wire • 10-23-2023
By Business Wire Business Wire • 05-31-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.